MktsMarkets

Abbott Laboratories
NYSE: ABTKey statistics
ABT News
Stories mentioning ABT from around the web — every one is an open thread, so give it a like or add your take.
Loading news…
Financial statements
As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.
| Line item | Q1 '26Mar 31 | Q4 '25Dec 31 | Q3 '25Sep 30 | Q2 '25Jun 30 | Q1 '25Mar 31 | Q4 '24Dec 31 | Q3 '24Sep 30 | Q2 '24Jun 30 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 11,164,000 | 11,459,000 | 11,369,000 | 11,142,000 | 10,358,000 | 10,974,000 | 10,635,000 | 10,377,000 |
| Cost of Goods Sold | 4,890,000 | 4,922,000 | 5,075,000 | 4,854,000 | 4,468,000 | 4,942,000 | 4,698,000 | 4,603,000 |
| Gross Profit | 6,274,000 | 6,537,000 | 6,294,000 | 6,288,000 | 5,890,000 | 6,032,000 | 5,937,000 | 5,774,000 |
| Operating Expenses | ||||||||
| Research & Development | 767,000 | 735,000 | 766,000 | 725,000 | 716,000 | 749,000 | 713,000 | 698,000 |
| Sales General & Admin | 3,740,000 | 3,129,000 | 3,051,000 | 3,091,000 | 3,061,000 | 2,907,000 | 2,895,000 | 2,936,000 |
| Total Operating Expenses | ||||||||
| Operating Income (Loss) | 1,345,000 | 2,251,000 | 2,057,000 | 2,052,000 | 1,693,000 | 1,911,000 | 1,859,000 | 1,669,000 |
| Interest Income | 106,000 | 78,000 | 77,000 | 71,000 | 82,000 | 91,000 | 91,000 | 82,000 |
| Interest Expense | ||||||||
| Other Expense | 159,000 | 134,000 | 150,000 | 137,000 | 127,000 | 154,000 | 121,000 | (10,000) |
| Pretax Income | 1,449,000 | 2,358,000 | 2,180,000 | 2,150,000 | 1,778,000 | 2,030,000 | 1,940,000 | 1,607,000 |
| Tax Provision | 372,000 | 582,000 | 536,000 | 371,000 | 453,000 | (7,199,000) | 294,000 | 305,000 |
| Net Income (Loss) | 1,077,000 | 1,776,000 | 1,644,000 | 1,779,000 | 1,325,000 | 9,229,000 | 1,646,000 | 1,302,000 |
| Earnings Per Share (Basic) | 0.62 | 1.02 | 0.94 | 1.02 | 0.76 | 5.30 | 0.94 | 0.74 |
| Earnings Per Share (Diluted) | 0.61 | 1.02 | 0.94 | 1.01 | 0.76 | 5.28 | 0.94 | 0.74 |
| Weighted Average Shares Outstanding (Basic) | 1,742,480 | 1,741,000 | 1,742,142 | 1,743,437 | 1,739,206 | 1,740,000 | 1,739,466 | 1,743,040 |
| Weighted Average Shares Outstanding (Diluted) | 1,747,073 | 1,748,000 | 1,749,361 | 1,750,835 | 1,747,220 | 1,748,000 | 1,747,597 | 1,751,153 |
Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.
About ABT
Abbott Laboratories (NYSE: ABT) is a stock listed on the New York Stock Exchange under the ticker symbol ABT. It last traded at $109.40 (Nov 3, 2026, 4:00 PM ET), down 0.7% on the day. That gives Abbott Laboratories a market capitalisation of $190.4B and a price-to-earnings ratio of 40.5.
Over the past 52 weeks ABT has traded between $81.97 and $132.03.
Revenue for the quarter ended Mar 31, 2026 was $11.2B; net income $1.1B. Revenue was up 7.8% from $10.4B in the quarter ended Mar 31, 2025.
| Quarter ended | Revenue | Net income | Margin |
|---|---|---|---|
| Mar 31, 2026 | $11.2B | $1.1B | 9.6% |
| Dec 31, 2025 | $11.5B | $1.8B | 15.5% |
| Sep 30, 2025 | $11.4B | $1.6B | 14.5% |
| Jun 30, 2025 | $11.1B | $1.8B | 16.0% |
From Abbott Laboratories’s quarterly (10-Q) filings, in US dollars.
Take a break — play a market game
Seven free games built around the markets. No download, no sign-up: they run right here in your browser.
Latest News
Market news from around the web — every story is an open thread, so give it a like or add your take.
Loading news…